Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Stephan A. Grupp(Children's Hospital of Philadelphia), Michael A. Pulsipher(Primary Children's Hospital), Michael R. Verneris(NHS Blood and Transplant), Hidefumi Hiramatsu(Kyoto University), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Françoise Méchinaud(Hotel Dieu Hospital), Gary Douglas Myers(Baylor College of Medicine), Susana Rives(Hospital Sant Joan de Déu Barcelona), Krysta Schlis(Oregon Health & Science University), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Jochen Buechner(Oslo University Hospital), Andrea Biondi(University of Milano-Bicocca), Shannon L. Maude(Children's Hospital of Philadelphia), Kapildeb Sen(Novartis (Switzerland)), Joerg Krueger(Hospital for Sick Children), Barbara De Moerloose(Ghent University Hospital), Nicolas Boissel(Inserm), Gregory A. Yanik(University of Michigan), Karen E. Thudium, Theodore W. Laetsch(Children's Hospital of Philadelphia), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Yiyun Zhang, André Baruchel(Hôpital Robert-Debré), Paul L. Martin(Duke University), Michael W. Boyer(University of Utah), Patricia A. Wood(Albany Stratton VA Medical Center Albany), Tetiana Taran(National Cancer Center), Carl H. June(University of Pennsylvania)
Blood
December 2, 2016
Cited by 83


Related Papers